Advertisement

Mycopathologia

, Volume 171, Issue 5, pp 349–354 | Cite as

Comparative Study of 250 mg/day Terbinafine and 100 mg/day Itraconazole for the Treatment of Cutaneous Sporotrichosis

  • Glaucia FrancesconiEmail author
  • Antonio Carlos Francesconi do Valle
  • Sonia Lambert Passos
  • Mônica Bastos de Lima Barros
  • Rodrigo de Almeida Paes
  • André Luiz Land Curi
  • José Liporage
  • Cássio Ferreira Porto
  • Maria Clara Gutierrez Galhardo
Article

Abstract

Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis.

Objective

To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis.

Materials and methods

A bidirectional cohort study was conducted on 55 patients receiving 250 mg/day terbinafine and 249 patients receiving 100 mg/day itraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1. Sporothrix schenckii was isolated by culture from all patients (age range: 18–70 years), who were submitted to the standard care protocol consisting of clinical and laboratory evaluation and periodic visits.

Results

Cure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (n = 4, 7.3%) and itraconazole (n = 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group.

Conclusion

Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.

Keywords

Sporotrichosis Itraconazole Terbinafine Treatment 

References

  1. 1.
    Barros MB, Schubach AO, Schubach TM, et al. An epidemic of sporotrichosis in Rio de Janeiro, Brazil: epidemiological aspects of a serie of cases. Epidemiol Infect. 2008;136(9):1192–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Barros MB, Schubach AO, Valle AC, et al. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis. 2004;38:529–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Marimon R, Cano J, Gené J, Sutton DA, Kawasaki M, Guarro J. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol. 2007;45(10):3198–206.PubMedCrossRefGoogle Scholar
  4. 4.
    Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:1255–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Rocha MM, Dassin T, Lira R. Sporotrichosis in patient with AIDS: report of a case and review. Rev Iberoam Micol. 2001;18(3):133–6.PubMedGoogle Scholar
  6. 6.
    Bustamante B, Campos PE. Sporotrichosis: a forgotten disease in the drug research agenda. Expert Rev Anti Infect Ther. 2004;2(1):85–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Song Y, Zhong SX, Yao L, Cai Q, Zhou JF, Liu YY, Huo SS, Li SS. Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2010. Epub ahead of print.Google Scholar
  8. 8.
  9. 9.
    Chapman SW, Pappas P, Kauffmann C, Smith EB, Dietze R, Tiraboschi-Foss N, Restrepo A, Bustamante AB, Opper C, Emady-Azar S, Bakshi R. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1,000 mg day(−1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004;47(1–2):62–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol. 1999;141(Suppl 56):36–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol. 1992;126(Suppl 39):51–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Galhardo MC, De Oliveira RM, Valle ACF, et al. Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Medical Mycology. 2008;46(2):141–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Kohler LM, Monteiro PC, Hahn RC, Hamdan JS. In vitro susceptibilities of isolates of Sporothrix schenckii to ITC and terbinafine. J Clin Microbiol. 2004;42(9):4319–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Marimon R, Serena C, Gené J, Cano J, Guarro J. In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother. 2008;52(2):732–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Tanuma H, Asai T, Abe M. Case report. Lymphatic vessel-type sporotrichosis immunohistochemical evaluation and cytokine expression pattern. Mycoses. 2001;44:316–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Francesconi G, Valle AF, Passos SRL, Reis R, Galhardo MCG. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2009;23(11):1273–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Noguchi H, Hiruma M, Kawada A. Case report. Sporotrichosis successfully treated with itraconazole in Japan. Mycoses. 1999;42:571–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Restrepo A, Robledo J, Gomez I, et al. Itraconazole therapy in lymphangitis and cutaneous sporotrichosis. Arch Dermatol. 1986;122:413–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Conti-Diaz IA, Civita E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses. 1992;35:153–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Faergemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol. 1991;71(4):322–6.PubMedGoogle Scholar
  21. 21.
  22. 22.
    Conti-Diaz IA. Epidemiology of sporotrichosis in Latin America. Mycopathologia. 1989;108:113–6.PubMedGoogle Scholar
  23. 23.
    Coskun B, Saral Y, et al. Sporotrichosis successfully treated with terbinafine and potassium iodide: Case report and review of literature. Mycopathologia. 2004;158:53–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Gupta AK, Lynde CW, Lauzin GJ, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol. 1998;138:529–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole. J Am Acad Dermatol. 1998;38:S37–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Kusuhara M, Hachisuka H, Sasai Y. Statistical survey of 150 cases with sporotrichosis. Mycopathologia. 1988;102:129–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Kwon-Chung KJ, Benett JE. Sporotrichosis. In: Kwon-Chung KJ, Benett JE, editors. Medical mycology. Philadelphia: Lea and Febiger; 1992. p. 707.Google Scholar
  28. 28.
    Naranjo CA, Sellers EM, Sander P, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Pappas PG, Tellez I, Deep AE, et al. Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Infect Dis. 2000;30:65–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Perez A. Terbinafine: a broad new spectrum of indications in several subcutaneous and systemic mycoses and parasitic diseases. Mycoses. 1999;42:150–1.Google Scholar
  31. 31.
    Sampaio S, Lacaz C, Almeida F. Clinical aspects on sporotrichosis in São Paulo. Rev Hosp Clin Fac Med São Paulo. 1954;9:391–402.Google Scholar
  32. 32.
    Trilles L, Fernandez-Torres B, Lazera MS, Wanke B, Schubach AO, Paes RA, Inza I, Guarro J. In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases. Antimicrob Agents Chemother. 2005;49(9):3952–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Vickers AE, Sinclair JR, Zollinger M, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999;27(9):1029–38.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Glaucia Francesconi
    • 1
    Email author
  • Antonio Carlos Francesconi do Valle
    • 1
  • Sonia Lambert Passos
    • 2
  • Mônica Bastos de Lima Barros
    • 3
  • Rodrigo de Almeida Paes
    • 4
  • André Luiz Land Curi
    • 5
    • 6
  • José Liporage
    • 3
  • Cássio Ferreira Porto
    • 1
  • Maria Clara Gutierrez Galhardo
    • 1
  1. 1.Laboratório de Pesquisa Clínica em Dermatologia InfecciosaInstituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz (FIOCRUZ)Rio de JaneiroBrazil
  2. 2.Laboratório de Epidemiologia ClínicaInstituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz (FIOCRUZ)Rio de JaneiroBrazil
  3. 3.Laboratório de InfectologiaInstituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz (FIOCRUZ)Rio de JaneiroBrazil
  4. 4.Laboratório de MicologiaInstituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz (FIOCRUZ)Rio de JaneiroBrazil
  5. 5.Laboratório de OftalmologiaInstituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz (FIOCRUZ)Rio de JaneiroBrazil
  6. 6.Serviço de FarmáciaInstituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz (FIOCRUZ)Rio de JaneiroBrazil

Personalised recommendations